Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Nov 1;63(9):1205-1208.
doi: 10.1093/cid/ciw516. Epub 2016 Aug 2.

Infrequent Clinical Assessment of Chronic Hepatitis B Patients in United States General Healthcare Settings

Philip R Spradling  1 , Jian Xing  1 , Loralee B Rupp  1 , Anne C Moorman  1 , Stuart C Gordon  1 , Eyasu T Teshale  1 , Mei Lu  1 , Joseph A Boscarino  1 , Connie M Trinacty  1 , Mark A Schmidt  1 , Scott D Holmberg  1 ; Chronic Hepatitis Cohort Study (CHeCS) Investigators
Collaborators, Affiliations

Infrequent Clinical Assessment of Chronic Hepatitis B Patients in United States General Healthcare Settings

Philip R Spradling et al. Clin Infect Dis. .

Abstract

Among 2338 chronic hepatitis B patients followed during 2006-2013 in the Chronic Hepatitis Cohort Study, 78% had ≥1 alanine aminotransferase and 37% had ≥1 hepatitis B virus DNA level assessed annually. Among cirrhotic patients, 46% never had hepatic imaging. Patients in this cohort were insufficiently monitored for disease activity and hepatocellular carcinoma.

Keywords: chronic hepatitis B; clinical assessment; general healthcare; monitoring.

PubMed Disclaimer

Conflict of interest statement

Potential conflicts of interest. S. C. G. receives grant/research support from AbbVie, Bristol-Myers Squibb, Conatus, CymaBay, Exalenz, Gilead Sciences, Intercept Pharmaceuticals, and Merck; is a consultant/advisor for AbbVie, Bristol-Myers Squibb, CVS Caremark, Gilead Sciences, Intercept, and Merck; and is on the speaker’s bureau for Gilead Sciences. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

Comment in

References

    1. Roberts H, Kruszon-Moran D, Ly KN, et al. Prevalence of chronic hepatitis B virus (HBV) infection in U.S. households: National Health and Nutrition Examination Survey (NHANES), 1988–2012. Hepatology 2016; 63:388–97. - PubMed
    1. Terrault NA, Bzowej NH, Chang KM, Hwang JP, Jonas MM, Murad MH. American Association for the Study of Liver Diseases (AASLD) guidelines for treatment of chronic hepatitis B. Hepatology 2016; 63:261–83. - PMC - PubMed
    1. Yapali S, Talaat N, Lok AS. Management of hepatitis B: our practice and how it relates to the guidelines. Clin Gastroenterol Hepatol 2014; 12:16–26. - PubMed
    1. European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol 2012; 57:167–85. - PubMed
    1. Liaw YF, Kao JH, Piratvisuth T, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B; a 2012 update. Hepatol Int 2012; 6:531–61. - PubMed

Publication types

Substances